A Phase I Study of Extended Field Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes

Fecha de inicio: 1 de noviembre de 1999

DISEASE CHARACTERISTICS: Histologically proven previously untreated invasive carcinoma of the uterine cervix Squamous cell carcinoma Adenosquamous carcinoma Adenocarcinoma TNM classification stage IIIB or IVA (FIGO classification stage IB, IIA, IIB, IIIA, IIIB, or IVA) Cytologically or histologically proven metastases to the para-aortic lymph nodes No more than 8 weeks since diagnosis No metastases to scalene nodes, intraperitoneal metastases, or metastases to other organs outside the radiation field at the time of original clinical and surgical staging Negative CT scan of the chest Patients with ureteral obstruction must be treated with stent or nephrostomy tube PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: At least 6 months Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 1.5 times normal SGOT no greater than 3 times normal Renal: Creatinine less than 2.0 mg/dL No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal transplantation) requiring modification of radiation fields Other: Not pregnant No septicemia or severe infection No other invasive malignancy within the past 3 years except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic chemotherapy for this or other malignancy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for this or other malignancy No prior radiotherapy to pelvis or abdomen Surgery: Not specified Other: No other prior therapy for this malignancy